Kendall Shirley, MD
Family Medicine · Anderson, SCNPI 1487003216
Payments from drug & device makers
Across 316 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$685
- AbbVie$571
- GSK$478
- Johnson & Johnson$330
- Pfizer$329
- AstraZeneca$200
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,604100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $685 |
| AbbVie(2 entities) | 42 | $571 |
| GSK | 26 | $478 |
| Johnson & Johnson | 27 | $330 |
| Pfizer | 21 | $329 |
| AstraZeneca | 16 | $200 |
| Amgen | 11 | $200 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $187 |
| Boehringer Ingelheim | 14 | $187 |
| Lilly USA, LLC | 13 | $178 |
| Sanofi-aventis U.S. LLC | 8 | $143 |
| Astellas Pharma US Inc | 8 | $117 |
| Exact Sciences | 6 | $89 |
| Amarin Pharma, Inc. | 4 | $84 |
| Kowa Pharmaceuticals America, Inc. | 6 | $77 |
| Dynavax Technologies Corporation | 3 | $67 |
| Biohaven Pharmaceuticals, Inc. | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $65 |
| Merck | 5 | $62 |
| Abbott | 4 | $60 |
| Xeris Pharmaceuticals, Inc. | 2 | $54 |
| Intuitive Surgical | 1 | $41 |
| Dexcom, Inc. | 3 | $41 |
| Novartis | 2 | $29 |
| Lundbeck LLC | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Philips North America LLC | 2 | $26 |
| Eisai Inc. | 2 | $26 |
| Mylan Specialty L.p. | 1 | $22 |
| Medtronic | 1 | $21 |
| Boston Scientific | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
How this compares
$4,604 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $91,554 |
| JardianceEmpagliflozin | 44 | $62,155 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $59,806 |
| TrulicityDulaglutide | 27 | $46,620 |
| FarxigaDapagliflozin Propanediol | 37 | $43,971 |
| EliquisApixaban | 43 | $43,555 |
| MounjaroTirzepatide | 14 | $31,066 |
| XareltoRivaroxaban | 23 | $23,947 |
| JanuviaSitagliptin Phosphate | 13 | $21,256 |
| VraylarCariprazine Hcl | 15 | $20,414 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $12,449 |
| LinzessLinaclotide | 11 | $11,216 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,089 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $6,642 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $6,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $685 | $91,55469 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $178 | $77,68741 claims |
| Boehringer IngelheimJardiance | $187 | $62,15544 claims |
| GSKTrelegy Ellipta | $478 | $59,80654 claims |
| AstraZenecaFarxiga, Symbicort | $200 | $51,06058 claims |
| PfizerEliquis | $329 | $43,55543 claims |
| MerckJanuvia, Janumet Xr | $62 | $33,70526 claims |
| AbbVieVraylar, Linzess, Synthroid | $571 | $33,31045 claims |
| Johnson & JohnsonXarelto | $330 | $23,94723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Anderson
- Erin CookseyAnderson$1.2M
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.